Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 5:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 725 matching trials from the live ClinicalTrials.gov search.
Conditions
Clear Cell Renal Carcinoma
Interventions
MK-3475, Bevacizumab
Drug
Lead sponsor
Arkadiusz Z. Dudek, MD
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 5 more
Conditions
Neoplasms by Site
Interventions
Relatlimab, Nivolumab, BMS-986213
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
1,482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
17
States / cities
La Jolla, California • Aurora, Colorado • Tampa, Florida + 14 more
Conditions
Unresectable Cutaneous Melanoma
Interventions
Axelopran, Nivolumab
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
KRAS peptide vaccine, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Carcinoma, Renal Cell
Interventions
DFF332, RAD001, PDR001, NIR178
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • St Louis, Missouri + 2 more
Conditions
Solid Tumor
Interventions
Debio 1143, Nivolumab
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Gainesville, Florida • Tampa, Florida • Chicago, Illinois + 7 more
Conditions
Metastatic Cancer, Solid Tumor, Head and Neck Cancer
Interventions
LYT-200, Tislelizumab
Drug
Lead sponsor
PureTech
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 7 more
Conditions
Gastric / Gastroesophageal Junction Adenocarcinoma
Interventions
Cadonilimab, CAPOX regimen, Nivolumab, Placebo
Drug
Lead sponsor
Akeso
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 9 more
Conditions
Solid Tumor, Adult
Interventions
CRB-701, Anti-PD-1
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Conditions
Metastatic Cancer
Interventions
Keytruda Injectable Product, Yervoy Injectable Product, GM-CSF, Non-ablative Cryosurgical freezing
Drug · Procedure
Lead sponsor
ImmunSYS, LLC
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Scottsdale, Arizona • Miami Lakes, Florida
Conditions
Non-small Cell Lung Cancer
Interventions
Trabedersen, Pembrolizumab
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Other Skin
Interventions
Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Avelumab, Pembrolizumab, Interferon Gamma-1b
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
MEDI7247
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Huntersville, North Carolina • Nashville, Tennessee
Conditions
Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma, Multiple Myeloma
Interventions
Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG, Antibiotics, Anti-viral agents, Anti-fungal agent, Anti-emetics
Biological · Diagnostic Test · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, Liver Metastasis
Interventions
nivolumab, tadalafil, oral vancomycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Billiary Track Cancer
Interventions
Gemcitabine, Cisplatin, Pembrolizumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions
Ozuriftamab Vedotin, Pembrolizumab, Evalstotug (BA3071), Cetuximab
Biological
Lead sponsor
BioAtla, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Newark, Delaware • Chicago, Illinois + 4 more
Conditions
Multiple Myeloma
Interventions
Autologous Stem Cell Transplant, Melphalan, Lenalidomide, MK-3475
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Ann Arbor, Michigan • Milwaukee, Wisconsin
Recruiting Phase 1Phase 2 Interventional

RAPA-201 Therapy of Solid Tumors

NCT05144698
Conditions
Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Malignant Melanoma, Esophageal Squamous Cell Carcinoma
Interventions
RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
Biological · Drug
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Conditions
Breast Neoplasms, Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Nivolumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
CV301, Pembrolizumab, Nivolumab
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Tampa, Florida • Indianapolis, Indiana • Metairie, Louisiana + 4 more
Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
Image-guided Radiation Therapy, Immunotherapy (physician's choice for standard of care immunotherapy)
Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer
Interventions
Lenalidomide, Pembrolizumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer, Non-small Cell Lung Carcinoma
Interventions
Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Jacksonville, Florida + 6 more